1. Sato S, Toshiyuki Uehara T et al. Impact of the Approval of Intravenous Recombinant Tissue Plasminogen Activator Therapy on the Processes of Acute Stroke Management in Japan. The Stroke Unit Multicenter Observational (SUMO) Study. Stroke 2009; 40: 30–4.
2. Kleindorfer D, Lindsell CJ, Brass L. National US Estimates of Recombinant Tissue Plasminogen Activator Use. Stroke 2008; 39: 924–8.
3. Ferro J, Melo T, Oliveira V, Crespo M, Canhão P, Pinto A: An analysis of the admission delay of acute stroke. Cerebrovasc Dis 1994; 4: 72–5.
4. Harraf F, Sharma AK, Brown MM, Lees KR et al. A multicentre observational study of presentation and early assessment of acute stroke. BMJ 2002; 325: 17–21.
5. Delay in Presentation and Evaluation for Acute Stroke. Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 2001; 32: 63–9.
Авторы
В.И.Скворцова, Н.А.Шамалов
Научно-исследовательский институт цереброваскулярной патологии и инсульта ГОУ ВПО РГМУ им. Н.И.Пирогова, Москва